The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1382
Intranasal Ketorolac (Sprix)
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

An intranasal formulation of ketorolac tromethamine (Sprix – Lutipold) has been approved by the FDA for short-term (up to 5 days) treatment of moderate to moderately severe pain in adults. It is the first nonsteroidal anti-inflammatory drug (NSAID) to become available in an intranasal formulation. Ketorolac tromethamine is also available in oral, ophthalmic and injectable formulations.1

NSAIDS FOR PAIN — Use of an NSAID in addition to an opioid analgesic for management of postoperative pain has been shown to improve pain control and reduce opioid use, but administration of an oral NSAID may not be possible immediately after surgery. Intravenous or intramuscular (IM) ketorolac has been shown to be comparable in analgesic efficacy to moderate doses of morphine, but can cause severe gastrointestinal toxicity and is not recommended for more than 5 ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Intranasal Ketorolac (Sprix)
Article code: 1382d
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian